Logo

American Heart Association

  127
  0


Final ID: Mo085

Direct effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on cardiomyocyte function as a potential therapy for Phospholamban cardiomyopathy

Abstract Body: Introduction: Phospholamban (PLN) cardiomyopathy is a dilated and arrhythmogenic cardiomyopathy caused by a single deletion of arginine in PLN gene (PLN-R14del). Clinically, It presents with heart failure, ventricular arrhythmias and sudden cardiac death, and there is still no effective and/or specific treatment besides the heart transplant.
Hypothesis: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown cardiovascular outcomes improvement in general heart failure patients in multiple clinical trials. We hypothesize that SGLT2 inhibitors could ameliorate the contractile dysfunction in PLN cardiomyopathy.
Goals: Identify whether there is a direct cardiac effect of SGLT2 inhibitors on PLN cardiomyopathy.
Approach: We used a human iPSC-derived cardiomyocyte (hiPSC-CMs) model of PLN cardiomyopathy that mimics the impaired contractility of the disease to evaluate the contractile function after 4 days of Empagliflozin treatment by using functional cellular imaging assays. Additionally, we evaluated the effect of Empagliflozin treatment on CaMKII phosphorylation and activation of apoptosis mediators by measuring protein expression. All the experiments were compared to results using a CRISPR-engineered isogenic (healthy) line control hiPSC-CMs.
Results: 4 days of Empagliflozin treatment significantly restored contractile function, decreased levels of CaMKII phosphorylation, and decreased apoptotic activity in hiPSC-CMs with PLN cardiomyopathy when compared to their healthy (isogenic) control.
Conclusions: Our study provided evidence that SGLT2 inhibitors might serve as a therapeutic strategy to ameliorate contractile dysfunction and suppress arrhythmia in PLN cardiomyopathy.
  • Hnatiuk, Anna  ( Stanford University , Palo Alto , California , United States )
  • Li, Alexander  ( Cardiovascular Institute, Stanford University , Palo Alto , California , United States )
  • Staudt, David  ( Stanford Childrens Health , Palo Alto , California , United States )
  • Serrano, Ricardo  ( Stanford University , Palo Alto , California , United States )
  • Mercola, Mark  ( STANFORD UNIVERSITY , Stanford , California , United States )
  • Author Disclosures:
    Anna Hnatiuk: DO NOT have relevant financial relationships | Alexander Li: DO NOT have relevant financial relationships | David Staudt: DO NOT have relevant financial relationships | Ricardo Serrano: No Answer | Mark Mercola: No Answer
Meeting Info:

Basic Cardiovascular Sciences

2024

Chicago, Illinois

Session Info:

Poster Session and Reception I

Monday, 07/22/2024 , 04:30PM - 07:00PM

Poster Session and Reception

More abstracts on this topic:
A combined approach of cardiac magnetic resonance and CardioMEMS to assess right ventricular dysfunction during exercise in HFpEF-PH

Bekhuis Youri, Bogaert Jan, La Gerche Andre, Claessen Guido, Janssens Stefan, Droogne Walter, Rosseel Thomas, Barrios Leticia, Verwerft Jan, Timmermans Philippe, Trenson Sander, Dresselaers Tom

HBI-3000: Pharmacological Conversion of Atrial Fibrillation With Unique Defense Against Excessive QT Interval Prolongation

Mason Jay, Roy Denis, Elliott Gary, Romano Suzanne, Pollack Charles, Gillings Dr Mireille, Riebman Jerome

More abstracts from these authors:
Function-First Assessment of TNNI3 Cardiomyopathy Variants To Predict Clinical Outcomes

Staudt David, Ashley Euan, Mercola Mark, Tran Peter, Floyd Brendan, Dunn Kyla, Han Dongju, Carhuamaca Xiomara, Hnatiuk Anna, Serrano Ricardo, Parikh Victoria

High-Throughput Functional Determination of TNNI3 Variant Pathogenicity

Staudt David, Tran Peter, Han Dongju, Serrano Ricardo, Mercola Mark

You have to be authorized to contact abstract author. Please, Login
Not Available